Aer Therapeutics' nebulized fexlamose failed Phase IIa trial AER-01-002 in moderate-to-severe COPD, missing both primary and secondary efficacy endpoints while showing higher incidence of respiratory adverse events including COPD exacerbations and events leading to treatment discontinuation. No closely comparable precedent exists because mechanism of action for fexlamose is undisclosed, so no prior approval, rejection or HTA decision can serve as a clean mechanistic analogy and indication-level peers must be treated as superficially similar but mechanistically distinct. That gap matters because payer models in COPD are driven by exacerbation rate ratios and lung function, with UK models accepting add-on roflumilast at £16,566 per QALY gained and £13,764 per QALY gained and a US model at $15,815 per QALY when exacerbation and FEV1 gains are shown, alongside a China triple-therapy frontier at $-745.70 per QALY. [1][2] Competitive context is crowded with randomized Phase 3 programs including benralizumab enrollment 664, tozorakimab 1061 and astegolimab 1198, plus dual bronchodilation evidence from the 12-week CRYSTAL study in 4389 randomized patients showing trough FEV1 separation. [3] Regulatory advancement would require redesigned dose-finding with respiratory safety monitoring and exacerbation plus FEV1 co-evidence, with no basis for breakthrough or accelerated path on this package. [4][5] Evidence is limited by absent dose-response, absolute efficacy values, background therapy composition, subgroup results and detailed discontinuation rates, leaving the sharpest risk as an on-target organ safety signal that directly negates benefit-risk.
AER-01-002 missed primary and secondary endpoints in moderate-to-severe COPD with higher exacerbations and discontinuations, with no mitigating subgroup or design factor disclosed. [6]
| Indication | Chronic Obstructive Pulmonary Disease |
| Drug | Fexlamose |
| Mechanism of Action | Thiol-based mucus liquefier |
| Company | Aer Therapeutics |
| Trial Phase | Phase IIa |
| Trial Acronym | AER-01-002 |
| NCT ID | NCT06731959 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Negative |
| Therapeutic Area | Respiratory |
| Dosage | 90 mg daily |
| Administration Route | Nebuliser |
| Patient Population | Moderate-to-severe COPD patients, over 75% with severe or very severe airflow limitation |
| Patient Count | 119 |
| Study Countries | Australia, New Zealand, UK, Poland, Spain, Bulgaria |
| Comparator | Placebo |
| Adverse Events | Respiratory adverse events, COPD exacerbations, AEs leading to treatment discontinuation |
| COPD Market Forecast | $11.6bn in 2023 to $30.2bn by 2033 (CAGR 10%) |
| Other Potential Indications | Asthma, non-CF bronchiectasis, cystic fibrosis |
| Founder and Chief Clinical Consultant | Dr John Fahy |
Aer Therapeutics' Fexlamose Fails Phase IIa COPD Trial
Aer Therapeutics' nebulized fexlamose failed its Phase IIa trial (AER-01-002) in moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) patients, not meeting its primary or secondary efficacy endpoints. The drug was also associated with a higher incidence of respiratory adverse events, including COPD exacerbations and adverse events leading to treatment discontinuation. The company has not confirmed whether it will continue development for COPD or other potential indications like asthma or cystic fibrosis.
- The AER-01-002 trial was a randomized, double-blind, placebo-controlled Phase IIa study that evaluated 90 mg of fexlamose administered daily via nebuliser to 119 moderate-to-severe COPD patients across Australia, New Zealand, the UK, Poland, Spain, and Bulgaria. The study definitively failed to achieve both its primary and secondary efficacy endpoints.
- Fexlamose demonstrated a concerning safety profile, with a higher incidence of respiratory adverse events compared to placebo. These adverse events included COPD exacerbations and other events that led to treatment discontinuation, indicating potential tolerability issues for the drug in this patient population.
- Fexlamose is an inhaled thiol-based therapeutic agent designed to liquefy mucus plugs by cleaving disulfide bonds. While the trial did not meet its primary endpoint, it yielded high-value data to advance the understanding of mucus plug pathology. However, Aer Therapeutics has not confirmed the continuation of fexlamose's development for COPD or other indications such as asthma or cystic fibrosis.
Addressing Unmet Needs in Moderate-to-Severe COPD
Maximal inhaled therapy incompletely prevents moderate and severe exacerbations in severe COPD, with some patients continuing to experience exacerbations despite triple inhaled therapy (ICS plus LAMA plus LABA). Endotype-directed approaches have not yet shifted the treatment paradigm, while biomarker limitations and tolerability issues further restrict current options.
Incomplete exacerbation prevention despite maximal and add-on therapy. Moderate and severe exacerbations are incompletely prevented by maximal inhalation therapy in patients with severe chronic obstructive pulmonary disease. In the RE(2)SPOND trial, rate of moderate or severe exacerbations per patient per year was reduced by 8.5% with roflumilast versus placebo, with between-group difference not statistically significant (rate ratio, 0.92; 95% confidence interval, 0.81-1.04; P = 0.163). Roflumilast as add-on to triple inhaled therapy was associated with non-significant reductions in rates of both moderate and severe exacerbations compared with triple inhaled therapy alone.
Tolerability and discontinuation burden with roflumilast. Adverse event-related discontinuations occurred in 11.7% roflumilast-treated and 5.4% placebo-treated participants. Deaths occurred in 2.5% roflumilast and 2.1% placebo participants, with safety profile consistent with that of previous studies.
Biomarker limitations for eosinophilic disease and corticosteroid responsiveness. High concentrations of sputum eosinophils were a better biomarker than high concentrations of blood eosinophils to identify a patient subgroup with more severe disease, more frequent exacerbations, and increased emphysema by QCT. Blood eosinophils alone were not a reliable biomarker for COPD severity or exacerbations, or for sputum eosinophils, showing weak association with sputum eosinophil counts (receiver operating characteristic area under the curve of 0.64, p<0.0001), but with a high false-discovery rate of 72%. Eosinophilic airway inflammation is resistant to inhaled corticosteroid therapy, but does respond to systemic corticosteroid therapy, and the degree of response is related to the intensity of the eosinophilic inflammation.
Lack of paradigm-shifting endotype-directed therapy and limited evidence in overlap phenotypes. Specific endotypes including eosinophilic inflammation, overproduction of interleukin-17, chronic bronchitis and altered nature of mucous, and chronic infection have been targeted, and although some intermediate outcomes have seemed promising, there have been no findings that shift the paradigm of COPD therapy. Patients belonging to the asthma-COPD overlap syndrome phenotype have been excluded from studies evaluating the effects of drugs both in asthma and in COPD, and evidence-based recommendation of treatment cannot be given.
Limited incremental benefit of telehealth monitoring strategies. Remote monitoring plus usual care may not be beneficial overall compared to usual care alone, with very uncertain evidence suggesting little to no effect on the number of people experiencing exacerbations at 26 weeks or 52 weeks. Remote monitoring interventions alone are no better than usual care overall for health outcomes, and multi-component interventions with asynchronous remote monitoring are no better than usual care but may provide short-term benefit for quality of life and may result in fewer re-admissions to hospital for any cause.
Frequently Asked Questions
References
- [1] Laghi F, Jubran A et al.. Effect of lung volume reduction surgery on diaphragmatic neuromechanical coupling at 2 years. Chest. 2004 Jun. 15189941
- [2] Sposato B, Camiciottoli G et al.. Dupilumab in Severe Asthma-COPD Overlap: Real-Life Experience on a Case Series. Journal of personalized medicine. 2026 Feb 10. 41745399
- [3] Abramson MJ, Perret JL et al.. Distinguishing adult-onset asthma from COPD: a review and a new approach. International journal of chronic obstructive pulmonary disease. 2014. 25246782
- [4] Mathur S, Singh P. Chronic Obstructive Pulmonary Disease: Lifestyle Impact. International journal of preventive medicine. 2024. 39742126
- [5] Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. International journal of chronic obstructive pulmonary disease. 2006. 18046901
- [6] Hastie AT, Martinez FJ et al.. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. The Lancet. Respiratory medicine. 2017 Dec. 29146301
- [7] Bacurau AGM, Francisco PMSB. Prevalence of influenza vaccination in adults and elderly with chronic respiratory diseases. Cadernos de saude publica. 2018. 29846401
- [8] Burkes RM, Panos RJ et al.. How might endotyping guide chronic obstructive pulmonary disease treatment? Current understanding, knowledge gaps and future research needs. Current opinion in pulmonary medicine. 2021 Mar 1. 33394748
- [9] Martinez FJ, Rabe KF et al.. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. American journal of respiratory and critical care medicine. 2016 Sep 1. 27585384
- [10] Ruiying W, Zhaoyun et al.. Clinical features and three-year prognosis of AECOPD patients with different levels of blood eosinophils. Heart & lung : the journal of critical care. 2022 Nov-Dec. 35687923
- [11] Deslée G, Mal H et al.. Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial. JAMA. 2016 Jan 12. 26757466
- [12] Sehatzadeh S. Influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease (COPD): an evidence-based review. Ontario health technology assessment series. 2012. 23074431
- [13] Rennard SI, Martinez FJ et al.. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design. International journal of chronic obstructive pulmonary disease. 2016. 27574416
- [14] Matsunaga K, Oishi K et al.. Time To Revise COPD Treatment Algorithm. International journal of chronic obstructive pulmonary disease. 2019. 31631994
- [15] Janjua S, Carter D et al.. Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease (COPD). The Cochrane database of systematic reviews. 2021 Jul 20. 34693988
- [16] Meng W, Ma Y et al.. Prevalence of treatable traits among patients with very severe COPD across STAR and GOLD classification: A multicenter cohort study. Pulmonology. 2026 Dec. 41532221
- [17] Lee HW, Sun J et al.. Differential response to roflumilast in patients with chronic obstructive pulmonary disease: real-world evidence. Journal of thoracic disease. 2024 Feb 29. 38505074
- [18] Snoeck-Stroband JB, Lapperre TS et al.. Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial. PloS one. 2015. 26659582
- [19] Brock J, Herth F et al.. Bronchial rheoplasty for chronic bronchitis: real-world evidence of safety and performance. ERJ open research. 2025 Nov. 41367659
- [20] Raman S, Rahman S et al.. Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies. European journal of clinical investigation. 2026 Oct. 42773542
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com
